ERKEN EVRE MİKOZİS FUNGOİDES’DE NÖTROFİL/LENFOSİT ORANI, TROMBOSİT/LENFOSİT ORANI VE ORTALAMA TROMBOSİT HACMİNİN PROGNOSTİK ÖNEMİ
Amaç: Mikozis Fungoides (MF), primer kutan T hücreli lenfomalar arasında en sık görülen lenfomadır. Erken evrelerde tanı alan birçok hastada prognoz oldukça iyi olmasına rağmen, bazı hastalarda hızla ileri evrelere geçiş görülebilmektedir. Son zamanlarda nötrofil/lenfosit oranı (NLO), trombosit/lenfosit oranı (TLO) ve ortalama trombosit hacmi (OTH) lenfomalarda prognostik belirteç olarak kullanılmakla birlikte, literatürde MF’li hastalarda bu konuda veri bulunmamaktadır. Gereç ve Yöntem: Dokuz Eylül Üniversitesi Tıp Fakültesi Deri ve Zührevi Hastalıklar Anabilim Dalı’nda erken evre MF tanısı koyulan ve en az 5 yıllık izlemi olan olguların verileri retrospektif olarak taranmıştır.Bulgular: Çalışmaya dâhil edilen 67 olgunun 15 (%22,4)’inde, hastalığın ileri evrelere geçiş gösterdiği belirlenmiştir. Vücut yüzey alanında ≥%10 tutulum, lenfopeni varlığı ve artmış NLO (>2,60) ve TLO’nun (>138,3) kötü prognoz ile ilişkili olduğu, NLO’nun ise bağımsız bir prognostik belirteç olduğu saptanmıştır. Sonuç: NLO ve TLO, MF’de erken evrelerdeki yüksek riskli hastaları belirlemek amacıyla kullanılabilecek kolay ve ucuz bir tarama yöntemi olabilir.
Prognostic significance of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and mean platelet volume in the early stage mycosis fungoides
Objective: Mycosis Fungoides (MF) is the most common lymphoma among the primary cutaneous T-cell lymphomas. Although the prognosis is excellent in many patients diagnosed in the early stages, rapid transition to advanced stages may be seen in some patients. Recently, the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) have been used as prognostic markers in lymphomas; however, there is no existing data in literature in patients with MF. Material and Method: The data of patients diagnosed with early stage MF having at least a 5-year follow up in the Skin and Venereal Diseases Department of Dokuz Eylul University Faculty of Medicine were retrospectively reviewed. Results: Transition to the advanced stages of the disease were observed in 15 (22.4%) of the 67 cases included in the study. The involvement ≥10% of the body surface area, presence of lymphopenia, and increased NLR (>2.60) and PLR (>138.3) were associated with poor prognosis, and NLR was found to be an independent prognostic marker. Conclusion: NLR and PLR may prove to be a simple and low cost screening method to identify high-risk patients in early stages of MF.
___
- Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017; 77: 57 - 74.
- Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70: 205.
- Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017; 12: 234 – 243.
- Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev 2017; 58: 1 – 13.
- Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 2017;8:37200-37207.
- Han Y, Wang J, Hong L, Sun L, Zhuang H, Sun B et al. Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer. Future Oncol 2017; 13: 51 – 61.
- Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 2018; 180: 545 – 549.
- Eren R, Nizam N, Doğu MH, Mercan S, Erdemir AV, Suyanı E. Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides. Ann Hematol 2016; 95: 1853 – 7.
- Cengiz FP, Emiroglu N, Ozkaya DB, Bahali AG, Su O, Onsun N. Prognostic Evaluation of Neutrophil/Lymphocyte Ratio in Patients with Mycosis Fungoides. Ann Clin Lab Sci 2017; 47: 25 – 28.
- Zeng Q, Liu Z, Li Q, Liu T. Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: A meta-analysis. Medicine (Baltimore) 2018; 97: e12678.
- Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010; 85: 896 – 9.
- Wang S, Ma Y, Sun L, Shi Y, Jiang S, Yu K et al. Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma. Biomed Res Int 2018; 2018: 9651254.
- Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol 2012; 138: 846 – 54.
- Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open 2017; 7: e017904.
- Kaito S, Kanemasa Y, Sasaki Y, Okuya T, Yamaguchi T, Funasaka C et al. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas. Int J Hematol 2018; 107: 451 – 459.
- Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Pozzi S et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol 2017; 35: 561 – 566.
- Feng X, Li L, Wu J, Zhang L, Sun Z, Li X et al. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. Oncologist 2019. pii: theoncologist. 2018-0789.
- Beltran BE, Aguilar C, Quiñones P, Morales D, Chavez JC, Sotomayor EM et al. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 2016; 57: 58 – 62.
- Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 2018; 18: 443.
- Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB. Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018; 2018: 5670949.
- Hu G, Liu Q, Ma JY, Liu CY. Prognostic Significance of Platelet-to-Lymphocyte Ratio in Cholangiocarcinoma: A Meta-Analysis. Biomed Res Int 2018; 2018: 7375169.
- Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23: 1204 – 12.
- Zhuang Q, Xiang L, Xu H, Fang F, Xing C, Liang B et al. The independent association of meanplatelet volume with overall survival in multiple myeloma.Oncotarget 2016; 7: 62640 ‐ 62646.
- Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impactof the mean platelet volume/platelet count ratio in terms of survival inadvanced non‐small cell lung cancer. Lung Cancer 2014; 83: 97 ‐ 101.
- Zhou S, Ma Y, Shi Y, Tang L, Zheng Z, Fang F et al. Mean platelet volume predicts prognosis in patients with diffuse large B-cell lymphoma. Hematol Oncol 2018; 36: 104 – 109.